<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19635170</article-id><article-id pub-id-type="pmc">2727510</article-id><article-id pub-id-type="publisher-id">1475-2840-8-41</article-id><article-id pub-id-type="doi">10.1186/1475-2840-8-41</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Lexis</surname><given-names>Chris PH</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>c.lexis@student.unimaas.nl</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Rahel</surname><given-names>Braim M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>brahel@viecuri.nl</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Meeder</surname><given-names>Joan G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jmeeder@viecuri.nl</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Zijlstra</surname><given-names>Felix</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>f.zijlstra@thorax.umcg.nl</email></contrib><contrib contrib-type="author" id="A5"><name><surname>van der Horst</surname><given-names>Iwan CC </given-names></name><xref ref-type="aff" rid="I2">2</xref><email>i.c.c.horst@thorax.umcg.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Cardiology, VieCuri Medical Centre, Venlo, The Netherlands</aff><aff id="I2"><label>2</label>Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>28</day><month>7</month><year>2009</year></pub-date><volume>8</volume><fpage>41</fpage><lpage>41</lpage><history><date date-type="received"><day>25</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Lexis et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Lexis et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.cardiab.com/content/8/1/41"/><abstract><sec><title>Introduction</title><p>The prevalence of diabetes is increasing rapidly, and individuals with diabetes are at high risk for cardiovascular disorders. Subsequently the percentage of patients with diabetes subjected to revascularisation, i.e. either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) also rises rapidly. The outcome of patients with diabetes after PCI is worse than for patients without diabetes. Restenosis is the main limiting factor of the long-term success of PCI. Although stents and antithrombotics improved outcome after PCI in both diabetics and non-diabetics, diabetics still have a worse prognosis. This leads to the suggestion that the restenosis mechanism in diabetics might be different from that in non-diabetics.</p></sec><sec><title>Conclusion</title><p>Several glucose lowering agents have been shown to influence the restenosis process and thus the outcome after PCI. Current data of especially metformin and thiazolidinediones indicate beneficial results as compared to insulin and sulfonylurea on restenosis. However, no large trials have been undertaken in which the effect of glucose lowering agents on restenosis is associated with improved outcome.</p><p>The purpose of this review is to summarize the effect of diabetes and glucose lowering agents on restenosis.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>In patients with diabetes, coronary artery disease (CAD) is often present [<xref ref-type="bibr" rid="B1">1</xref>]. In comparison with patients without diabetes, CAD is manifest earlier in life [<xref ref-type="bibr" rid="B1">1</xref>]. Especially women with diabetes have a significantly higher risk of developing CAD in comparison with men [<xref ref-type="bibr" rid="B2">2</xref>]. The calibre of "normal" coronary arteries at coronary angiography is smaller in patients with diabetes [<xref ref-type="bibr" rid="B3">3</xref>]. Diabetics have more multi vessel coronary artery disease and form less often collaterals [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Not only have patients with diabetes more plaques, the plaques are more inflamed and necrotic, forming a risk factor for rupture and therefore myocardial infarction (MI) [<xref ref-type="bibr" rid="B6">6</xref>]. After MI diabetics have a worse prognosis [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Patients with type 2 diabetes without known CAD have a risk of a MI comparable to non-diabetics with a previous history of MI [<xref ref-type="bibr" rid="B1">1</xref>]. It is therefore reasonable that CAD is accountable for 70&#x02013;80% of the diabetes related mortality [<xref ref-type="bibr" rid="B7">7</xref>]. Despite improvement of coronary interventions, outcome in patients with diabetes is impaired [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Restenosis is the main limiting factor of the long-term success of percutaneous coronary interventions (PCI) [<xref ref-type="bibr" rid="B9">9</xref>]. Possibly the restenosis mechanism in diabetics might be different from that in non-diabetics. The purpose of this review is to summarize the influence of diabetes on coronary restenosis and to summarize the effect of glucose lowering agents on restenosis and outcome.</p></sec><sec><title>Mechanism of Disease</title><sec><title>Restenosis in diabetics</title><p>Diabetes is one of the most important risk factors for restenosis after stent implantation, with odds ratios of 1.9 to 2.5 [<xref ref-type="bibr" rid="B10">10</xref>]. Diabetes leads to more extensive neointimal hyperplasia, plaque formation, altered hemodynamics and inadequate compensatory remodeling (table <xref ref-type="table" rid="T1">1</xref>) [<xref ref-type="bibr" rid="B8">8</xref>]. Restenotic intimal hyperplasia in diabetics differs from non-diabetics [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Diabetic vascular smooth muscle cells exhibit increased rates of proliferation, leading to luminal narrowing [<xref ref-type="bibr" rid="B11">11</xref>]. Furthermore, restenotic intimal hyperplasia in diabetics has increased macrophage infiltration [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>], lipid-rich and collagen-rich sclerotic content [<xref ref-type="bibr" rid="B8">8</xref>]. Diabetics have more vaso vasorum neovascularisation, leading to intraplaque haemorrhage [<xref ref-type="bibr" rid="B12">12</xref>]. Atherosclerotic laesions in diabetics are more prone to rupture [<xref ref-type="bibr" rid="B11">11</xref>]. Furthermore, progression of atherosclerotic plaques is accelerated in diabetics [<xref ref-type="bibr" rid="B8">8</xref>]. More extensive neointimal hyperplasia and more rapid plaque formation in diabetics leads to more restenosis and less stable atherosclerotic plaques.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Key processes in restenosis in diabetics; the processes are specified to the elevated (&#x02191;) or decreased (&#x02193;) factors contributing to the elevated risk of restenosis in diabeticscompared to non-diabetics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Influence of 4 Key Factors on Restenosis in Diabetics</th></tr></thead><tbody><tr><td align="left">Process</td><td align="left">Factor</td></tr><tr><td colspan="2"><hr/></td></tr><tr><td align="left">Proinflammatory state</td><td align="left">&#x02191; C-peptide</td></tr><tr><td/><td align="left">&#x02191; Resistin</td></tr><tr><td/><td align="left">&#x02191; CRP</td></tr><tr><td/><td align="left">&#x02191; Il-12</td></tr><tr><td colspan="2"><hr/></td></tr><tr><td align="left">Prothrombotic state</td><td align="left">&#x02191; P2Y-receptor</td></tr><tr><td/><td align="left">&#x02191; Endothelial damage by O2-radicals</td></tr><tr><td colspan="2"><hr/></td></tr><tr><td align="left">Accelerated and unstable plaque formation</td><td align="left">&#x02191; Vascular smooth muscle cell proliferation</td></tr><tr><td/><td align="left">&#x02191; Macrophage infiltration</td></tr><tr><td/><td align="left">&#x02191; Lipid-rich</td></tr><tr><td/><td align="left">&#x02191; Collagen-rich</td></tr><tr><td/><td align="left">&#x02191; Vaso vasorum neovascularization</td></tr><tr><td colspan="2"><hr/></td></tr><tr><td align="left">Haemodynamics</td><td align="left">&#x02193; Vessel lumen diameter</td></tr><tr><td/><td align="left">&#x02191; Multivessel disease</td></tr><tr><td/><td align="left">&#x02191; Viscosity</td></tr></tbody></table></table-wrap><p>Several factors can account for the more extensive CAD in patients with diabetes. First, diabetic patients are more likely to have (co-) morbidities, among which are cardiovascular risk factors such as the metabolic syndrome. According to the National Cholesterol Education Program (NCEP) Expert Panel ATP-III-criteria (2001) the metabolic syndrome consist of 3 or more of 5 risk factors: hyperglycaemia, hypertension, decreased levels of HDL, elevated levels of triglycerides and abdominal (visceral) obesity [<xref ref-type="bibr" rid="B13">13</xref>]. The metabolic syndrome is associated with a proinflammatory and prothrombotic state [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Several molecular mechanisms have been implicated in hyperglycaemic-induced endothelial damage: activation of protein-kinase C isoforms, increased hexosamine pathway flux, increased advanced glycation end product formation, increased polyol pathway flux and activation of the proinflammatory nuclear transcription factor kappa-B [<xref ref-type="bibr" rid="B7">7</xref>]. All these mechanisms are associated with overproduction of reactive oxygen species, which lead to endothelial dysfunction, decreased vasodilatation and promotion of atherosclerotic plaque formation [<xref ref-type="bibr" rid="B7">7</xref>]. Plaque formation is one of the forces behind restenosis.</p><p>Peroxisome proliferator activated receptors (PPARs) play an important role in the atherosclerotic process. Especially PPAR-gamma &#x02013; a subfamily &#x02013; is potent in reducing plaque inflammation, in inhibiting expression of adhesion molecules and in inhibiting formation of cytokines (e.g. interleukin 12 [IL-12]) [<xref ref-type="bibr" rid="B7">7</xref>]. It is known IL-12 is an important factor in the pathophysiology of atherosclerosis and leads to up-regulation of T1-helper response, which is associated with CAD [<xref ref-type="bibr" rid="B14">14</xref>]. Wegner et al (2008) demonstrated that IL-12 levels are elevated in type 2 diabetics based on fasting proinsulin due to insulin resistance [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Furthermore, insulin resistance leads to upregulation of the P2Y-receptor-pathway, a platelet membrane protein [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>In patients with diabetes increased levels of C-peptide, a cleavage product of proinsulin, circulate. C-peptide promotes monocyte and T-lymphocyte recruitment into the vessel wall [<xref ref-type="bibr" rid="B16">16</xref>]. Walcher et al (2006) showed that in early arteriosclerotic lesions of diabetic subjects, C-peptide colocalized adherent to vascular smooth muscle cells (VSMCs) in the media [<xref ref-type="bibr" rid="B16">16</xref>]. C-peptide induced phosphorylation of Src-kinase, as well as activation of the extracellular signal-regulated kinase 1/2 (ERK 1/2) and phosphatidylinositol 3-kinase (PI3K) leading to increased cell proliferation.</p><p>Another pathway involved in proliferation of VSMCs is through the effects induced by resistin, an adipokine, which is elevated in diabetes [<xref ref-type="bibr" rid="B17">17</xref>]. One study has shown that resistin has a proinflammatory effect on endothelial cells [<xref ref-type="bibr" rid="B17">17</xref>]. Calabro et al (2004) showed that VSMC proliferation was induced by resistin [<xref ref-type="bibr" rid="B17">17</xref>]. Resistin induces VSMC proliferation through both ERK 1/2 and Akt signaling pathways. Furthermore, On et al (2007) demonstrated that elevated preprocedural serum resistin levels may prove to be a useful biological marker for coronary artery disease and restenosis in patients with type 2 diabetes [<xref ref-type="bibr" rid="B18">18</xref>].</p></sec></sec><sec><title>Coronary Interventions and Restenosis</title><sec><title>Coronary stents</title><p>The long-term benefit of balloon angioplasty is mainly limited by restenosis of the treated segment, occurring in one third to half of all treated patients [<xref ref-type="bibr" rid="B19">19</xref>]. Restenosis causes recurrent myocardial ischemia and therefore necessitates additional revascularisation [<xref ref-type="bibr" rid="B19">19</xref>]. Initially, bare metal stents (BMS) were introduced to overcome flow limiting dissections following balloon angioplasty. In addition it was shown that stents resulted in a lower rate of restenosis and recurrent ischemia. Stents prevent vessel recoil and negative remodeling &#x02013; important steps in luminal narrowing &#x02013; and thereby reduce the possibility of restenosis [<xref ref-type="bibr" rid="B20">20</xref>]. Intimal hyperplasia, another important step in luminal narrowing, is not prevented by stenting and is the main reason for in-stent restenosis.</p><p>Drug-eluting stents (DES) are covered with polymers of immunosuppressive agents e.g. paclitaxel, sirolimus, and zotarolimus, which are progressively eluted the first weeks after implantation. DES treatment in both diabetics and non-diabetics leads to a reduction of target vessel revascularization (TVR) and restenosis after PCI in comparison to BMS [<xref ref-type="bibr" rid="B10">10</xref>]. A recent meta-analysis by Stettler et al (2009) demonstrated that in 3852 diabetics and 10947 non-diabetics DES and BMS have comparable hazard ratios for mortality [<xref ref-type="bibr" rid="B21">21</xref>]. Furthermore, this study confirmed that DES lead to a decrease in revascularization rates compared with BMS in people both with and without diabetes.</p><p>Jensen et al (2009) compared paclitaxel eluting stents and sirolimus eluting stents in 74 diabetics and found that paclitaxel eluting stents had increased lumen reduction [<xref ref-type="bibr" rid="B22">22</xref>]. Fr&#x000f6;bert et al (2009) compared four types of drug eluting stents in 8,231 patients with diabetes, and found significant differences in restenosis rates, favouring the paclitaxel-eluting stents [<xref ref-type="bibr" rid="B23">23</xref>]. However, Lee et al (2009) demonstrated in the Drug-Eluting-Stents in Diabetes (DES-DIABETES) trial with 400 patients that on the long-term the sirolimus-eluting stent lead to a reduction of restenosis, TVR and major adverse cardiac events (MACE) [<xref ref-type="bibr" rid="B24">24</xref>]. These results were confirmed by a meta-analysis of 16 randomized trials by Sch&#x000f6;mig et al (2007) [<xref ref-type="bibr" rid="B25">25</xref>].</p></sec><sec><title>Bare metal stent versus coronary artery bypass grafting</title><p>In non-diabetics there is no difference in mortality between PCI with BMS and coronary artery bypass grafting (CABG) for multivessel disease, whereas in diabetics CABG is thought to have a favourable outcome in comparison with PCI [<xref ref-type="bibr" rid="B26">26</xref>]. The Bypass Angioplasty Revascularization Investigation (BARI)-trial (2007) demonstrated that in 1,476 non-diabetics there was no difference between elective PCI and CABG, for both short-term and long-term survival, with a 10-year mortality rate of 23.0% in the PCI group and 22.7% in the CABG group. However, among the subgroup of patients with treated diabetes (n = 353), CABG had a long-term benefit over PCI, based on reduced cardiac mortality in the patients undergoing CABG, with mortality rates of PCI versus CABG of 54.5% versus 42.1%, respectively [<xref ref-type="bibr" rid="B26">26</xref>]. The recent meta-analysis by Hlatky et al (2009) showed that in 10 trials with 7,812 patients confirmed the long-term benefit of CABG [<xref ref-type="bibr" rid="B27">27</xref>]. In the 1,233 patients with diabetes the 5-year mortality rate was significantly lower with 12.3% in the CABG group versus 20.0% in the PCI group. In the recent Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) (2009) with 2368 type 2 diabetes patients the absolute rates of major adverse cardiac events were equal in patients treated with PCI (n = 798) or CABG (n = 378), i.e. 23% versus 22.4% [<xref ref-type="bibr" rid="B28">28</xref>]. In the BARI 2D both BMS and DES were used.</p></sec><sec><title>Drug eluting stents versus coronary artery bypass grafting</title><p>Conversely, when comparing DES with CABG for multivessel disease, the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial by Serruys et al (2009) with 1800 patients showed that the rates of myocardial infarction and mortality were similar between PCI and CABG groups [<xref ref-type="bibr" rid="B29">29</xref>]. Major adverse cardiac and cerebrovascular events (MACCE) were significantly increased in the PCI group, mainly due to higher rates of revascularization. In the SYNTAX patients with more severe coronary artery disease, and especially those with diabetes, CABG was related to a higher freedom from re-intervention. These results were corroborated by Tarantini et al (2009), Daemen et al (2008), Briguori et al (2007) and Lee et al (2007), respectively including 220, 159, 218 and 205 diabetics [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B33">33</xref>].</p></sec></sec><sec><title>Antiplatelet Agents</title><sec><title>Thienopyridines</title><p>Insulin resistance leads to upregulation of the P2Y-receptor-pathway, a platelet membrane protein [<xref ref-type="bibr" rid="B15">15</xref>]. The P2Y-receptor is the target of the active metabolite of clopidogrel. Post-PCI this results in increased platelet reactivity in diabetics [<xref ref-type="bibr" rid="B15">15</xref>]. Therefore, a higher dose of thienopyridines seems needed in diabetics to attain an adequate antithrombotic regiment [<xref ref-type="bibr" rid="B34">34</xref>]. Illustrating the importance of antithrombotic therapy in diabetics, Stettler et al (2009) demonstrated that, in contrast to non-diabetics, drug eluting stents in diabetics are only safe to use if adequate antiplatelet therapy is administered [<xref ref-type="bibr" rid="B21">21</xref>]. Wiviott et al (2008) demonstrated in 3,146 patients with diabetes that prasugrel compared with clopidogrel leads to a reduction in cardiovascular death, MI and stroke (12.2% versus 17%) [<xref ref-type="bibr" rid="B35">35</xref>]. This illustrates the potential to overcome the relative antiplatelet drug resistance of diabetes with novel pharmacologic agents.</p></sec><sec><title>Glycoprotein IIb/IIIa receptor blockade</title><p>During PCI both profound vessel wall injury and plaque rupture occur. This triggers activation of the coagulation cascade, and adhesion, activation and aggregation of platelets. Platelets express more glycoprotein (GP) IIb/IIIa receptors in diabetics and have a tendency to aggregate, especially in the presence of hyperglycemia [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Type 2 diabetics on insulin have greater platelet aggregation than type 2 diabetics non treated with insulin [<xref ref-type="bibr" rid="B36">36</xref>]. Labinaz et al (2002) compared GP IIb/IIIa receptor blockers in PCIs in diabetics (n = 466) and non-diabetics (n = 1,595) [<xref ref-type="bibr" rid="B37">37</xref>]. The group of patients receiving GP IIb/IIIa receptor blockers had significant decreased rates of mortality, TVR and MI. However, the relative risk reduction for diabetics was similar to the reduction in non-diabetics.</p></sec></sec><sec><title>Glucose Lowering Agents and Restenosis</title><p>The effect of treatment with glucose lowering agents on macrovascular disease is not well established. In the European Heart Survey a pronounced decrease in cardiovascular events in patients with newly detected diabetes prescribed glucose lowering agents compared with those not receiving such treatment was observed [<xref ref-type="bibr" rid="B38">38</xref>]. Several retrospective analyses of databases showed differences in coronary revascularization and MI in patients treated with different regimens (table <xref ref-type="table" rid="T2">2</xref>). The major recognized limitation of these analyses is the bias of patients with a higher risk profile treated with insulin or combination therapy [<xref ref-type="bibr" rid="B39">39</xref>]. The above-mentioned BARI 2D also showed that after a follow-up period of more than 3 years in patients treated with PCI that no survival benefit could be observed between patients treated with metformin or TZDs (insulin sensitization, 10.2%) as compared to insulin or sulfonylurea (insulin provision, 11.4%) [<xref ref-type="bibr" rid="B28">28</xref>]. However, the rate of major cardiovascular events was 3.8% lower in the insulin sensitization group treated with PCI, albeit non-significant. The effect of the individual glucose lowering agents was not reported (yet). The effect of glucose lowering, i.e. more strict versus moderate glucose control, on outcome has been extensively investigated. In a meta-analysis (2009) of 5 large trials the rate of non-fatal myocardial infarction was significantly lower in the stricter compared to the moderate glucose control group, 10.0% versus 12.3% [<xref ref-type="bibr" rid="B40">40</xref>]. Whether strict glucose control, irrespective of specific glucose lowering agents, is related to a reduction of restenosis is not known.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Elevated (&#x02191;) or decreased (&#x02193;) risk of restenosis, target laesion vascularization (TLR), death or myocardial infarction (MI) of the different groups of glucose lowering agents after PCI.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5">Risk Modulation of Glucose Lowering Agents in Diabetics After PCI</th></tr></thead><tbody><tr><td align="left">Agent</td><td align="left">Restenosis</td><td align="left">TLR</td><td align="left">Death</td><td align="left">MI</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">TZDs</td><td align="left">&#x02193;</td><td align="left">&#x02193;</td><td align="left">&#x02193;</td><td align="left">-</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Sulfonylurea</td><td align="left">&#x02191;</td><td align="left">-</td><td align="left">&#x02191;</td><td align="left">-</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Biguanides</td><td align="left">-</td><td align="left">&#x02193;</td><td align="left">-</td><td align="left">&#x02193;</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Insulin</td><td align="left">&#x02191;</td><td align="left">&#x02191;</td><td align="left">&#x02191;</td><td align="left">&#x02191;</td></tr></tbody></table></table-wrap><sec><title>Thiazolidinediones</title><p>Thiazolidinediones (TZDs) are peroxisome proliferator activated receptors (PPAR)-gamma agonists. They decrease insulin resistance, levels of CRP, fibrinogen, LDL-cholesterol, triglycerides and resistin in comparison with placebo [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. TZDs inhibit VSMC proliferation, ameliorating intimal hyperplasia and restenosis [<xref ref-type="bibr" rid="B42">42</xref>]. Under high glucose conditions the inhibitory activity of VSMC proliferation by pioglitazone and rosiglitazone is enhanced, in contract to troglitazone [<xref ref-type="bibr" rid="B42">42</xref>].</p><p>Several studies have suggested the preventive effects of TZDs on atherosclerosis, restenosis, in-stent restenosis, and reocclusion after PCI in patients with type 2 diabetes. Takagi et al (2002) showed in a randomized study that in 55 patients with 60 lesions troglitazone was associated with reduced angiographic in-stent restenosis and neointimal tissue proliferation [<xref ref-type="bibr" rid="B43">43</xref>]. Choi et al (2004) found in a case-control study with 83 patients treated with rosiglitazone that at 6 months a significant reduction in restenosis rate, greater minimal lumen stent diameter and albeit non-significant lower TVR [<xref ref-type="bibr" rid="B44">44</xref>]. Nishio et al (2006) observed in randomized study with 54 patients that treatment with pioglitazone attenuated neointimal thickening regardless of the type of PCI and resulted in less late luminal loss [<xref ref-type="bibr" rid="B45">45</xref>]. The meta-analysis of Rosmarakis et al in 2007 already showed that TZDs decrease the need for target vessel revascularization when 5 trials with 235 patients were analyzed [<xref ref-type="bibr" rid="B46">46</xref>]. The meta-analysis by Geng et al published in 2009 consisted of 8 trials with 366 patients and showed that TZDs were associated with a significant reduction in the risk of in-stent restenosis in both diabetic and non-diabetic patients [<xref ref-type="bibr" rid="B47">47</xref>]. They also observed a reduction in late lumen loss, percent diameter stenosis, neointimal area/volume, and target lesion revascularization. Recently, Finn et al (2009) randomly assigned 65 diabetics to rosiglitazone or placebo and could not confirm the above described results on luminal loss [<xref ref-type="bibr" rid="B48">48</xref>]. An interesting observation was made by Nishio et al (2006), i.e. that in 38 type 2 diabetics similar restenosis rates were present in patients treated with either a BMS with pioglitazone or sirolimus-eluting stent without pioglitazone [<xref ref-type="bibr" rid="B49">49</xref>]. Fang et al (2007) demonstrated that rosiglitazone therapy in comparison to standard antidiabetic therapy without rosiglitazone in type 2 diabetics leads to a significant decrease in restenosis and mortality [<xref ref-type="bibr" rid="B50">50</xref>]. However, the intervention group significantly used more insulin and biguanides, which might lead to bias of the observed effects. In a study with 417 patients referred for stress testing to evaluate chest pain by Kapinya et al (2008), 222 were treated with conventional therapy only (insulin and insulin secretagogues) and 195 as being treated with insulin sensitizers (metformin and thiazolidinediones) [<xref ref-type="bibr" rid="B51">51</xref>]. The rate of ischemia and MI was not significantly lower in patients treated with thiazolidinediones. In the Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE)-trial, Nissen et al (2008) demonstrated that in patients with type 2 diabetes and coronary artery disease treatment with pioglitazone compared with glimepiride results in a significantly lower rate of progression of coronary atherosclerosis, as measured with intravascular ultrasound [<xref ref-type="bibr" rid="B52">52</xref>]. The patients receiving pioglitazone also had significantly reduced levels of CRP, triglycerides and HbA1c and an increase in HDL. Nonetheless, this trial did not show any significant differences in clinical outcome between pioglitazone and glimepiride. Recently, Clementi et al (2009) demonstrated in 25 patients with diabetes that administration of pioglitazone combined with atorvastatin leads to a significant regression of coronary atherosclerosis [<xref ref-type="bibr" rid="B53">53</xref>].</p></sec><sec><title>Biguanides</title><p>The precise mechanism of action of biguanides, i.e. metformin, is not completely elucidated. Metformin has insulin sensitizing effects, and may therefore have cardiovascular effects [<xref ref-type="bibr" rid="B54">54</xref>]. In the previously described study by Kapinya et al (2004), only the 125 patients on metformin had lower rates of ischemia and MI [<xref ref-type="bibr" rid="B51">51</xref>]. In diabetics undergoing PCI, Kao et al (2004) showed that metformin-therapy in comparison with insulin and sulfonylurea was associated with a reduced risk of MI and mortality [<xref ref-type="bibr" rid="B54">54</xref>]. It is not clear whether the superiority of metformin therapy in this trial is due to beneficial effects of the metformin or is due to possible adverse effects of the sulfonylurea on atherosclerosis. In the study by Walker et al (2008) it was observed that patients treated with metformin were less likely to need revascularization or suffer from MI compared to other treatment regimens [<xref ref-type="bibr" rid="B39">39</xref>]. Comparable results were observed by Casscells et al with 232,000 diabetics (2008) [<xref ref-type="bibr" rid="B55">55</xref>]. On the other hand in a post-hoc analysis of the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI)-2 trial with 1181 patients no differences on cardiovascular mortality were observed, although metformin was associated with a significant lower rate of non-fatal MI and stroke as compared to sulfonylurea or insulin treatment [<xref ref-type="bibr" rid="B56">56</xref>].</p><p>Adversely, metformin therapy may also lead to progression of coronary artery disease. Chronic use of metformin leads to decreased intestinal absorption of group B vitamins and folate. These deficiencies lead to elevated levels of homocysteine, which accelerates progression of cardiovascular disease due to adverse effects on platelets, endothelium and clothing factors [<xref ref-type="bibr" rid="B57">57</xref>].</p></sec><sec><title>Sulfonylurea</title><p>Sulfonylurea act through binding to the sulfonylurea receptor on the surface of pancreatic &#x003b2; cells. This results in closure of the potassium channels and thereby depolarization of the cell membrane and, in turn, opening of voltage-dependent calcium channels. The influx of calcium causes microtubules to contract and the exocytosis of insulin from vesicles. Garratt et al (1999) report that sulfonylurea drugs are associated with an increased risk of in-hospital mortality among 185 diabetic patients undergoing angioplasty for acute myocardial infarction [<xref ref-type="bibr" rid="B58">58</xref>]. No association between sulfonylurea drugs and <italic>late </italic>adverse events after primary PCI has been observed. The explanation for this early risk is not an increase in ventricular arrhythmias, but reflects the deleterious effects of sulfonylurea drugs on myocardial tolerance for ischemia and reperfusion. Blockade of K-ATP-channels, which is the target of sulfonylurea drugs, promotes insulin release in pancreatic B-cells, but also affects in certain sulfonylurea drugs cardiac tissue and coronary arteries [<xref ref-type="bibr" rid="B59">59</xref>]. This leads to greater vulnerability of the myocardium to ischemia, which results in the increased clinical manifestations of ischemia [<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B60">60</xref>].</p><p>Sulfonylurea drug use lead to elevated IL-12 serum levels in type-2 diabetics, induced by peripheral insulin resistance and beta cell dysfunction, as expressed by fasting serum proinsulin levels. Therefore, according to the hypothesis by Wegner et al, sulfonylurea drugs can promote atherosclerosis [<xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec><title>Insulin</title><p>Huang et al demonstrated that high levels of insulin are potent in stimulating VSMC proliferation [<xref ref-type="bibr" rid="B61">61</xref>]. The clinical relevance of this observation has yet to be investigated. In all the above-described studies patients treated with insulin had higher rates of either ischemia or infarction.</p></sec></sec><sec><title>Conclusion</title><p>Diabetes is a major risk factor for adverse events after PCI. Diabetics have higher rates of mortality, myocardial infarction and target vessel revascularisation than non-diabetics. Recent therapeutical antithrombotic and percutaneous developments improved the prognosis both for diabetics and non-diabetics, thereby maintaining a worse prognosis for diabetics.</p><p>The exact mechanism of restenosis is not yet completely understood, although several contributing factors have been identified. Several glucose lowering drugs influence the restenosis process. Current data of especially metformin and thiazolidinediones indicate beneficial results as compared with insulin and sulfonylurea. However, no large prospective trials in which the clinical impact of these drugs on restenosis is investigated have been undertaken.</p><p>The prognosis of diabetics undergoing PCI remains worse than non-diabetics. Possibly the best way to improve the prognosis of diabetics undergoing PCI is to prevent diabetes or to pursue adequate diabetes regulation.</p><sec><title>Future area of interest</title><p>Due to the negative influence of diabetes on prognosis after PCI, glucose lowering therapy might have a substantial influence on coronary restenosis and the worse prognosis of diabetics. Future studies might determine whether or not the type of glucose lowering agent has influence on restenosis after PCI.</p></sec></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>The authors responsibilities were as follows &#x02013; CL: study design, data interpretation, data collection and drafting the manuscript; BR and IH: study design, data interpretation and critical revision of the manuscript for important intellectual content; JM and FZ: study design and critical revision of the manuscript for important intellectual content. All authors approved the final manuscript.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Flaherty</surname><given-names>JD</given-names></name><name><surname>Davidson</surname><given-names>CJ</given-names></name><article-title>Diabetes and coronary revascularisation</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>1501</fpage><lpage>1508</lpage><pub-id pub-id-type="pmid">15784875</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Huxley</surname><given-names>R</given-names></name><name><surname>Barzi</surname><given-names>F</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><article-title>Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies</article-title><source>BMJ</source><year>2006</year><volume>332</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">16371403</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Mosseri</surname><given-names>M</given-names></name><name><surname>Nahir</surname><given-names>M</given-names></name><name><surname>Rozenman</surname><given-names>Y</given-names></name><name><surname>Lotan</surname><given-names>C</given-names></name><name><surname>Admon</surname><given-names>D</given-names></name><name><surname>Raz</surname><given-names>I</given-names></name><name><surname>Gotsman</surname><given-names>MS</given-names></name><article-title>Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease</article-title><source>Cardiology</source><year>1998</year><volume>89</volume><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">9524010</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Dortimer</surname><given-names>AC</given-names></name><name><surname>Shenoy</surname><given-names>PN</given-names></name><name><surname>Shiroff</surname><given-names>RA</given-names></name><name><surname>Leaman</surname><given-names>DM</given-names></name><name><surname>Babb</surname><given-names>JD</given-names></name><name><surname>Liedtke</surname><given-names>AJ</given-names></name><name><surname>Zelis</surname><given-names>R</given-names></name><article-title>Diffuse coronary artery disease in diabetic patients: fact or fiction?</article-title><source>Circulation</source><year>1978</year><volume>57</volume><fpage>133</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">618380</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Abaci</surname><given-names>A</given-names></name><name><surname>O&#x0011f;uzhan</surname><given-names>A</given-names></name><name><surname>Kahraman</surname><given-names>S</given-names></name><name><surname>Eryol</surname><given-names>NK</given-names></name><name><surname>Unal</surname><given-names>S</given-names></name><name><surname>Arin&#x000e7;</surname><given-names>H</given-names></name><name><surname>Ergin</surname><given-names>A</given-names></name><article-title>Effects of diabetes mellitus on formation of coronary collateral vessels</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>2239</fpage><lpage>2242</lpage><pub-id pub-id-type="pmid">10226087</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Burke</surname><given-names>AP</given-names></name><name><surname>Kolodgie</surname><given-names>FD</given-names></name><name><surname>Zieske</surname><given-names>A</given-names></name><name><surname>Fowler</surname><given-names>DR</given-names></name><name><surname>Weber</surname><given-names>DK</given-names></name><name><surname>Varghese</surname><given-names>PJ</given-names></name><name><surname>Farb</surname><given-names>A</given-names></name><name><surname>Virmani</surname><given-names>R</given-names></name><article-title>Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2004</year><volume>24</volume><fpage>1266</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">15142859</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Moreno</surname><given-names>PR</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><article-title>New Aspects in the pathogenesis of diabetic atherothrombosis</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><fpage>2293</fpage><lpage>2300</lpage><pub-id pub-id-type="pmid">15607389</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><name><surname>Kalidindi</surname><given-names>S</given-names></name><name><surname>Wolski</surname><given-names>K</given-names></name><name><surname>Moon</surname><given-names>KW</given-names></name><name><surname>Sipahi</surname><given-names>I</given-names></name><name><surname>Schoenhagen</surname><given-names>P</given-names></name><name><surname>Nissen</surname><given-names>SE</given-names></name><article-title>Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">18634979</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Gruentzig</surname><given-names>A</given-names></name><article-title>Transluminal dilatation of coronary artery stenosis (letter)</article-title><source>Lancet</source><year>1978</year><volume>1</volume><fpage>263</fpage><pub-id pub-id-type="pmid">74678</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Airoldi</surname><given-names>F</given-names></name><name><surname>Briguori</surname><given-names>C</given-names></name><name><surname>Iakovou</surname><given-names>I</given-names></name><name><surname>Stankovic</surname><given-names>G</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G</given-names></name><name><surname>Carlino</surname><given-names>M</given-names></name><name><surname>Chieffo</surname><given-names>A</given-names></name><name><surname>Montorfano</surname><given-names>M</given-names></name><name><surname>Cosgrave</surname><given-names>J</given-names></name><name><surname>Michev</surname><given-names>I</given-names></name><name><surname>Rogacka</surname><given-names>R</given-names></name><name><surname>Sangiorgi</surname><given-names>GM</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><article-title>Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis</article-title><source>Am J Cardiol</source><year>2006</year><volume>97</volume><fpage>1182</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">16616023</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Moreno</surname><given-names>PR</given-names></name><name><surname>Murcia</surname><given-names>AM</given-names></name><name><surname>Palacios</surname><given-names>IF</given-names></name><name><surname>Leon</surname><given-names>MN</given-names></name><name><surname>Bernardi</surname><given-names>VH</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Fallon</surname><given-names>JT</given-names></name><article-title>Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>2180</fpage><lpage>2184</lpage><pub-id pub-id-type="pmid">11056089</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Faries</surname><given-names>PL</given-names></name><name><surname>Rohan</surname><given-names>DI</given-names></name><name><surname>Takahara</surname><given-names>H</given-names></name><name><surname>Wyers</surname><given-names>MC</given-names></name><name><surname>Contreras</surname><given-names>MA</given-names></name><name><surname>Quist</surname><given-names>WC</given-names></name><name><surname>King</surname><given-names>GL</given-names></name><name><surname>Logerfo</surname><given-names>FW</given-names></name><article-title>Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion and migration</article-title><source>J Vasc Surg</source><year>2001</year><volume>33</volume><fpage>601</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">11241133</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><collab>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</collab><article-title>Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>2486</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">11368702</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Wegner</surname><given-names>M</given-names></name><name><surname>Winiarska</surname><given-names>H</given-names></name><name><surname>Bobkiewicz-Koz&#x00142;owska</surname><given-names>T</given-names></name><name><surname>Dworacka</surname><given-names>M</given-names></name><article-title>IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas</article-title><source>Cytokine</source><year>2008</year><volume>42</volume><fpage>312</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">18397831</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>van Werkum</surname><given-names>JW</given-names></name><name><surname>Heestermans</surname><given-names>AA</given-names></name><name><surname>Plokker</surname><given-names>HW</given-names></name><name><surname>ten Berg</surname><given-names>JM</given-names></name><article-title>Clinical, biochemical and genetical resistance to clopidogrel in a patient with recurrent stent thrombosis</article-title><source>Int J Cardiol</source><year>2007</year><volume>116</volume><fpage>136</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">16870279</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Walcher</surname><given-names>D</given-names></name><name><surname>Babiak</surname><given-names>C</given-names></name><name><surname>Poletek</surname><given-names>P</given-names></name><name><surname>Rosenkranz</surname><given-names>S</given-names></name><name><surname>Bach</surname><given-names>H</given-names></name><name><surname>Betz</surname><given-names>S</given-names></name><name><surname>Durst</surname><given-names>R</given-names></name><name><surname>Gr&#x000fc;b</surname><given-names>M</given-names></name><name><surname>Hombach</surname><given-names>V</given-names></name><name><surname>Strong</surname><given-names>J</given-names></name><name><surname>Marx</surname><given-names>N</given-names></name><article-title>C-peptide induces vascular smooth muscle cell proliferation; involvement of Src-Kinase, Phosphatidylinositol 3-Kinase, and Extracellular Signal-Regulated Kinase 1/2</article-title><source>Circ Res</source><year>2006</year><volume>99</volume><fpage>1181</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">17068290</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Calabro</surname><given-names>P</given-names></name><name><surname>Samudio</surname><given-names>I</given-names></name><name><surname>Willerson</surname><given-names>JT</given-names></name><name><surname>Yeh</surname><given-names>ET</given-names></name><article-title>Resistin promotes smooth muscle cell proliferation through activation of extracellular signal regulated kinase 1/2 and phosphatidfylinositol 3-kinase pathways</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>3335</fpage><lpage>3340</lpage><pub-id pub-id-type="pmid">15545519</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>On</surname><given-names>YK</given-names></name><name><surname>Park</surname><given-names>HK</given-names></name><name><surname>Hyon</surname><given-names>MS</given-names></name><name><surname>Jeon</surname><given-names>ES</given-names></name><article-title>Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients</article-title><source>Circ J</source><year>2007</year><volume>71</volume><fpage>868</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">17526982</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>de Jaegere</surname><given-names>P</given-names></name><name><surname>Kiemeneij</surname><given-names>F</given-names></name><name><surname>Macaya</surname><given-names>C</given-names></name><name><surname>Rutsch</surname><given-names>W</given-names></name><name><surname>Heyndrickx</surname><given-names>G</given-names></name><name><surname>Emanuelsson</surname><given-names>H</given-names></name><name><surname>Marco</surname><given-names>J</given-names></name><name><surname>Legrand</surname><given-names>V</given-names></name><name><surname>Materne</surname><given-names>P</given-names></name><name><surname>Belardi</surname><given-names>J</given-names></name><name><surname>Sigwart</surname><given-names>U</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Goy</surname><given-names>JJ</given-names></name><name><surname>Heuvel</surname><given-names>P van den</given-names></name><name><surname>Delcan</surname><given-names>J</given-names></name><name><surname>Morel</surname><given-names>MA</given-names></name><article-title>A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">8041413</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Haude</surname><given-names>M</given-names></name><name><surname>Erbel</surname><given-names>R</given-names></name><name><surname>Issa</surname><given-names>H</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><article-title>Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz-Schatz stents</article-title><source>J am Coll Cardiol</source><year>2002</year><volume>39</volume><fpage>183</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">11788206</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Stettler</surname><given-names>C</given-names></name><name><surname>Alleman</surname><given-names>S</given-names></name><name><surname>Wandel</surname><given-names>S</given-names></name><name><surname>Kastrati</surname><given-names>A</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Sch&#x000f6;mig</surname><given-names>A</given-names></name><name><surname>Pfisterer</surname><given-names>ME</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>de Lezo</surname><given-names>JS</given-names></name><name><surname>Goy</surname><given-names>JJ</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Sabat&#x000e9;</surname><given-names>M</given-names></name><name><surname>Suttorp</surname><given-names>MJ</given-names></name><name><surname>Kelbaek</surname><given-names>H</given-names></name><name><surname>Spaulding</surname><given-names>C</given-names></name><name><surname>Menichelli</surname><given-names>M</given-names></name><name><surname>Vermeersch</surname><given-names>P</given-names></name><name><surname>Dirksen</surname><given-names>MT</given-names></name><name><surname>Cervinka</surname><given-names>P</given-names></name><name><surname>De Carlo</surname><given-names>M</given-names></name><name><surname>Erglis</surname><given-names>A</given-names></name><name><surname>Chechi</surname><given-names>T</given-names></name><name><surname>Ortolani</surname><given-names>P</given-names></name><name><surname>Schalij</surname><given-names>MJ</given-names></name><name><surname>Diem</surname><given-names>P</given-names></name><name><surname>Meier</surname><given-names>B</given-names></name><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>J&#x000fc;ni</surname><given-names>P</given-names></name><article-title>Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis</article-title><source>BMJ</source><year>2008</year><volume>29</volume><fpage>a1331</fpage></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Jensen</surname><given-names>LO</given-names></name><name><surname>Maeng</surname><given-names>M</given-names></name><name><surname>Mintz</surname><given-names>GS</given-names></name><name><surname>Christiansen</surname><given-names>EH</given-names></name><name><surname>Hansen</surname><given-names>KN</given-names></name><name><surname>Galloe</surname><given-names>A</given-names></name><name><surname>Kelbaek</surname><given-names>H</given-names></name><name><surname>Lassen</surname><given-names>JF</given-names></name><name><surname>Thuesen</surname><given-names>L</given-names></name><name><surname>Thayssen</surname><given-names>P</given-names></name><article-title>Serial intravascular ultrasound analysis of peri-stent remodeling and proximal and distal edge effects after sirolimus-eluting or paclitaxel-eluting stent implantation in patients with diabetes mellitus</article-title><source>Am J Cardiol</source><year>2009</year><volume>103</volume><fpage>1083</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">19361594</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Fr&#x000f6;bert</surname><given-names>O</given-names></name><name><surname>Lagerqvist</surname><given-names>B</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Lindb&#x000e4;ck</surname><given-names>J</given-names></name><name><surname>Stenestrand</surname><given-names>U</given-names></name><name><surname>James</surname><given-names>SK</given-names></name><article-title>Differences in restenosis rate with different drug-eluting stens in patients with and without diabetes mellitus</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><fpage>1660</fpage><lpage>1667</lpage><pub-id pub-id-type="pmid">19406341</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Yun</surname><given-names>SC</given-names></name><name><surname>Park</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Hong</surname><given-names>MK</given-names></name><name><surname>Rhee</surname><given-names>KS</given-names></name><name><surname>Chae</surname><given-names>JK</given-names></name><name><surname>Ko</surname><given-names>JK</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>SW</given-names></name><name><surname>Jeong</surname><given-names>JO</given-names></name><name><surname>Seong</surname><given-names>IW</given-names></name><name><surname>Cho</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>NH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Chun</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><article-title>A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 2-year clinical outcomes of the DES-DIABETES trial</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><fpage>812</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">19245976</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Sch&#x000f6;mig</surname><given-names>A</given-names></name><name><surname>Dibra</surname><given-names>A</given-names></name><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Mehilli</surname><given-names>J</given-names></name><name><surname>Su&#x000e1;rez de Lezo</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Goy</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Di Lorenzo</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>J&#x000fc;ni</surname><given-names>P</given-names></name><name><surname>Pfisterer</surname><given-names>ME</given-names></name><name><surname>Meier</surname><given-names>B</given-names></name><name><surname>Kastrati</surname><given-names>A</given-names></name><article-title>A meta-analysis of 16 randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in patients with coronary artery disease</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><fpage>1373</fpage><lpage>1380</lpage><pub-id pub-id-type="pmid">17903638</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><collab>The BARI investigators</collab><article-title>The final 10-year follow-up results from the BARI randomized trial</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>49</volume><fpage>1600</fpage><lpage>1606</lpage><pub-id pub-id-type="pmid">17433949</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Hlatky</surname><given-names>MA</given-names></name><name><surname>Boothroyd</surname><given-names>DB</given-names></name><name><surname>Bravata</surname><given-names>DM</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Booth</surname><given-names>J</given-names></name><name><surname>Brooks</surname><given-names>MM</given-names></name><name><surname>Carrie</surname><given-names>D</given-names></name><name><surname>Clayton</surname><given-names>TC</given-names></name><name><surname>Danchin</surname><given-names>N</given-names></name><name><surname>Flatcher</surname><given-names>M</given-names></name><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Hueb</surname><given-names>WA</given-names></name><name><surname>K&#x000e4;hler</surname><given-names>J</given-names></name><name><surname>Kelsy</surname><given-names>SF</given-names></name><name><surname>King</surname><given-names>SB</given-names></name><name><surname>Kosinki</surname><given-names>AS</given-names></name><name><surname>Lopes</surname><given-names>N</given-names></name><name><surname>McDonald</surname><given-names>KM</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Serruys</surname><given-names>P</given-names></name><name><surname>Sigwart</surname><given-names>U</given-names></name><name><surname>Stables</surname><given-names>RH</given-names></name><name><surname>Owens</surname><given-names>DK</given-names></name><name><surname>Pocock</surname><given-names>SJ</given-names></name><article-title>Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1190</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">19303634</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><collab>BARI 2D Study Group</collab><name><surname>Frye</surname><given-names>RL</given-names></name><name><surname>August</surname><given-names>P</given-names></name><name><surname>Brooks</surname><given-names>MM</given-names></name><name><surname>Hardison</surname><given-names>RM</given-names></name><name><surname>Kelsy</surname><given-names>SF</given-names></name><name><surname>MacGregor</surname><given-names>JM</given-names></name><name><surname>Orchard</surname><given-names>TJ</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Genuth</surname><given-names>SM</given-names></name><name><surname>Goldberg</surname><given-names>SH</given-names></name><name><surname>Hlatky</surname><given-names>MA</given-names></name><name><surname>Jones</surname><given-names>TL</given-names></name><name><surname>Molitch</surname><given-names>ME</given-names></name><name><surname>Nesto</surname><given-names>RW</given-names></name><name><surname>Sako</surname><given-names>EY</given-names></name><name><surname>Sobel</surname><given-names>BE</given-names></name><article-title>A randomized trial of therapies for type 2 diabetes and coronary artery disease</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>2503</fpage><lpage>2515</lpage><pub-id pub-id-type="pmid">19502645</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Kappetein</surname><given-names>P</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><name><surname>St&#x000e5;hle</surname><given-names>E</given-names></name><name><surname>Feldman</surname><given-names>TE</given-names></name><name><surname>Brand</surname><given-names>M van den</given-names></name><name><surname>Bass</surname><given-names>EJ</given-names></name><name><surname>Van Dyck</surname><given-names>N</given-names></name><name><surname>Leadley</surname><given-names>K</given-names></name><name><surname>Dawkins</surname><given-names>KD</given-names></name><name><surname>Mohr</surname><given-names>FW</given-names></name><article-title>Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>961</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">19228612</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Tarantini</surname><given-names>G</given-names></name><name><surname>Ramondo</surname><given-names>A</given-names></name><name><surname>Napodano</surname><given-names>M</given-names></name><name><surname>Favaretto</surname><given-names>E</given-names></name><name><surname>Gardin</surname><given-names>A</given-names></name><name><surname>Bilato</surname><given-names>C</given-names></name><name><surname>Nesseris</surname><given-names>G</given-names></name><name><surname>Tarzia</surname><given-names>V</given-names></name><name><surname>Cademartiri</surname><given-names>F</given-names></name><name><surname>Gerosa</surname><given-names>G</given-names></name><name><surname>Iliceto</surname><given-names>S</given-names></name><article-title>PCI versus CABG for multivessel coronary disease in diabetics</article-title><source>Catheter Cardiovasc Interv</source><year>2009</year><volume>73</volume><fpage>50</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19089938</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Daemen</surname><given-names>J</given-names></name><name><surname>Kuck</surname><given-names>KH</given-names></name><name><surname>Macaya</surname><given-names>C</given-names></name><name><surname>Legrand</surname><given-names>V</given-names></name><name><surname>Vrolix</surname><given-names>M</given-names></name><name><surname>Carrie</surname><given-names>D</given-names></name><name><surname>Sheiban</surname><given-names>I</given-names></name><name><surname>Suttorp</surname><given-names>MJ</given-names></name><name><surname>Vranckx</surname><given-names>P</given-names></name><name><surname>Rademaker</surname><given-names>T</given-names></name><name><surname>Goedhart</surname><given-names>D</given-names></name><name><surname>Schuijer</surname><given-names>M</given-names></name><name><surname>Wittebols</surname><given-names>K</given-names></name><name><surname>Macours</surname><given-names>N</given-names></name><name><surname>Stoll</surname><given-names>HP</given-names></name><name><surname>Serruys</surname><given-names>PW</given-names></name><article-title>Multivessel coronary revascularization in patients with and without diabetes mellitus</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>1957</fpage><lpage>1967</lpage><pub-id pub-id-type="pmid">19055986</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Briguori</surname><given-names>C</given-names></name><name><surname>Condorelli</surname><given-names>G</given-names></name><name><surname>Airoldi</surname><given-names>F</given-names></name><name><surname>Focaccio</surname><given-names>A</given-names></name><name><surname>D'Andrea</surname><given-names>D</given-names></name><name><surname>Cannavale</surname><given-names>M</given-names></name><name><surname>Abarghouei</surname><given-names>AA</given-names></name><name><surname>Giordano</surname><given-names>S</given-names></name><name><surname>De Vivo</surname><given-names>F</given-names></name><name><surname>Ricciardelli</surname><given-names>B</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><article-title>Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus</article-title><source>Am J Cardiol</source><year>2007</year><volume>99</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">17350364</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Jamal</surname><given-names>F</given-names></name><name><surname>Kedia</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Kapoor</surname><given-names>N</given-names></name><name><surname>Forrester</surname><given-names>J</given-names></name><name><surname>Czer</surname><given-names>L</given-names></name><name><surname>Zimmer</surname><given-names>R</given-names></name><name><surname>DeRobertis</surname><given-names>M</given-names></name><name><surname>trento</surname><given-names>A</given-names></name><name><surname>Makker</surname><given-names>RR</given-names></name><article-title>Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease</article-title><source>Int J Cardiol</source><year>2007</year><volume>123</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17292983</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Shoemaker</surname><given-names>SB</given-names></name><name><surname>Desai</surname><given-names>B</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Charlton</surname><given-names>RK</given-names></name><name><surname>Bernardo</surname><given-names>E</given-names></name><name><surname>Zenni</surname><given-names>MM</given-names></name><name><surname>Guzman</surname><given-names>LA</given-names></name><name><surname>Bass</surname><given-names>TA</given-names></name><name><surname>Costa</surname><given-names>MA</given-names></name><article-title>Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study</article-title><source>Circulation</source><year>2007</year><volume>115</volume><fpage>1</fpage><lpage>9</lpage></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Meisel</surname><given-names>S</given-names></name><name><surname>Dalby</surname><given-names>AJ</given-names></name><name><surname>Verheugt</surname><given-names>FW</given-names></name><name><surname>Goodman</surname><given-names>SG</given-names></name><name><surname>Corbalan</surname><given-names>R</given-names></name><name><surname>Purdy</surname><given-names>DA</given-names></name><name><surname>Murphy</surname><given-names>SA</given-names></name><name><surname>McCabe</surname><given-names>CH</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><article-title>Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>1626</fpage><lpage>1636</lpage><pub-id pub-id-type="pmid">18757948</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Bernardo</surname><given-names>E</given-names></name><name><surname>Ramirez</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>MA</given-names></name><name><surname>Sabat&#x000e9;</surname><given-names>M</given-names></name><name><surname>Jimenez-Quevedo</surname><given-names>P</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>R</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Escaned</surname><given-names>J</given-names></name><name><surname>Alfonso</surname><given-names>F</given-names></name><name><surname>Banuelos</surname><given-names>C</given-names></name><name><surname>Bass</surname><given-names>TA</given-names></name><name><surname>Macaya</surname><given-names>C</given-names></name><name><surname>Fernandez-Ortiz</surname><given-names>A</given-names></name><article-title>Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">16843179</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Labinaz</surname><given-names>M</given-names></name><name><surname>Madan</surname><given-names>M</given-names></name><name><surname>O'Shea</surname><given-names>JO</given-names></name><name><surname>Kilaru</surname><given-names>R</given-names></name><name><surname>Chin</surname><given-names>W</given-names></name><name><surname>Pieper</surname><given-names>K</given-names></name><name><surname>McGuire</surname><given-names>DK</given-names></name><name><surname>Sucedo</surname><given-names>JF</given-names></name><name><surname>Talley</surname><given-names>JD</given-names></name><name><surname>Lui</surname><given-names>H</given-names></name><name><surname>Kitt</surname><given-names>MM</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Tcheng</surname><given-names>JT</given-names></name><article-title>Comparison of one-year outcomes following coronary artery stenting in diabetic versus non-diabetic patients (from the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy [ESPRIT] trial)</article-title><source>Am J Cardiol</source><year>2002</year><volume>90</volume><fpage>585</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">12231081</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Anselmino</surname><given-names>M</given-names></name><name><surname>Ohrvik</surname><given-names>J</given-names></name><name><surname>Malmberg</surname><given-names>K</given-names></name><name><surname>Standl</surname><given-names>E</given-names></name><name><surname>Ryd&#x000e9;n</surname><given-names>L</given-names></name><article-title>Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">18156611</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Walker</surname><given-names>AM</given-names></name><name><surname>Koro</surname><given-names>CE</given-names></name><name><surname>Landon</surname><given-names>J</given-names></name><article-title>Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000&#x02013;2007</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2008</year><volume>17</volume><fpage>760</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">18383443</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Ray</surname><given-names>KK</given-names></name><name><surname>Seshasai</surname><given-names>SR</given-names></name><name><surname>Wijesuriya</surname><given-names>S</given-names></name><name><surname>Sivakumaran</surname><given-names>R</given-names></name><name><surname>Nethercott</surname><given-names>S</given-names></name><name><surname>Preiss</surname><given-names>D</given-names></name><name><surname>Erquo</surname><given-names>S</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name><article-title>Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1765</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">19465231</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Sidhu</surname><given-names>JS</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><name><surname>Kaski</surname><given-names>JC</given-names></name><article-title>The effects of rosiglitazone, a peroxisome proliferator-activated receptorgamma agonist, on markers of endothelial cell activation, C-reactive protein and fibrinogen levels in non-diabetic coronary artery disease patients</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>42</volume><fpage>1757</fpage><lpage>1763</lpage><pub-id pub-id-type="pmid">14642684</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Little</surname><given-names>PJ</given-names></name><name><surname>Osman</surname><given-names>N</given-names></name><name><surname>de Dios</surname><given-names>ST</given-names></name><name><surname>Cemerlang</surname><given-names>N</given-names></name><name><surname>Ballinger</surname><given-names>M</given-names></name><name><surname>Nigro</surname><given-names>J</given-names></name><article-title>Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions</article-title><source>Cardiovasc Diabetol</source><year>2007</year><volume>6</volume><fpage>33</fpage><pub-id pub-id-type="pmid">17963526</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Yamamuro</surname><given-names>A</given-names></name><name><surname>Tamita</surname><given-names>K</given-names></name><name><surname>Yamabe</surname><given-names>K</given-names></name><name><surname>Katayama</surname><given-names>M</given-names></name><name><surname>Morioka</surname><given-names>S</given-names></name><name><surname>Akasaka</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><article-title>Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus</article-title><source>Am J Cardiol</source><year>2002</year><volume>89</volume><fpage>318</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">11809434</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Ko</surname><given-names>YG</given-names></name><name><surname>Ahn</surname><given-names>CW</given-names></name><name><surname>Jang</surname><given-names>Y</given-names></name><name><surname>Lim</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Cha</surname><given-names>BS</given-names></name><article-title>Preventive effects on rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>2654</fpage><lpage>2660</lpage><pub-id pub-id-type="pmid">15505001</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Nishio</surname><given-names>K</given-names></name><name><surname>Sakurai</surname><given-names>M</given-names></name><name><surname>Kusuyama</surname><given-names>T</given-names></name><name><surname>Shigemitsu</surname><given-names>M</given-names></name><name><surname>Fukui</surname><given-names>T</given-names></name><name><surname>Kawamura</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>S</given-names></name><name><surname>Konno</surname><given-names>N</given-names></name><name><surname>Katagiri</surname><given-names>T</given-names></name><article-title>A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">16373904</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Rosmarakis</surname><given-names>ES</given-names></name><name><surname>Falagas</surname><given-names>ME</given-names></name><article-title>Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials</article-title><source>Am Heart J</source><year>2007</year><volume>154</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">17584567</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Geng</surname><given-names>DF</given-names></name><name><surname>Jin</surname><given-names>DM</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>JF</given-names></name><article-title>Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials</article-title><source>Atherosclerosis</source><year>2009</year><volume>202</volume><fpage>521</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">18602105</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Finn</surname><given-names>AV</given-names></name><name><surname>Oh</surname><given-names>JS</given-names></name><name><surname>Hendricks</surname><given-names>M</given-names></name><name><surname>Daher</surname><given-names>M</given-names></name><name><surname>Cagliero</surname><given-names>E</given-names></name><name><surname>Byrne</surname><given-names>RM</given-names></name><name><surname>Nadelson</surname><given-names>J</given-names></name><name><surname>Crimins</surname><given-names>J</given-names></name><name><surname>Kastrati</surname><given-names>A</given-names></name><name><surname>Sch&#x000f6;mig</surname><given-names>A</given-names></name><name><surname>Bruskina</surname><given-names>O</given-names></name><name><surname>Palacios</surname><given-names>I</given-names></name><name><surname>John</surname><given-names>MC</given-names></name><name><surname>Gold</surname><given-names>HK</given-names></name><article-title>Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo</article-title><source>Am Heart J</source><year>2009</year><volume>157</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">19185649</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Nishio</surname><given-names>K</given-names></name><name><surname>Shigemitsu</surname><given-names>M</given-names></name><name><surname>Kodama</surname><given-names>Y</given-names></name><name><surname>Konno</surname><given-names>N</given-names></name><name><surname>Katagiri</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><article-title>Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with type 2 diabetes mellitus</article-title><source>Cardiovasc Revasc Med</source><year>2009</year><volume>10</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">19159848</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Fang</surname><given-names>CC</given-names></name><name><surname>Ng Yao</surname><given-names>YT</given-names></name><name><surname>Yi-Chen</surname></name><name><surname>Yu</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name><name><surname>Wang</surname><given-names>SP</given-names></name><article-title>Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience</article-title><source>Angiology</source><year>2007</year><volume>58</volume><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">18024934</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Kapinya</surname><given-names>K</given-names></name><name><surname>Nijjar</surname><given-names>PS</given-names></name><name><surname>Stanek</surname><given-names>M</given-names></name><name><surname>Amanullah</surname><given-names>A</given-names></name><article-title>Insulin-sensitizing antihyperglycaemic medications are associated with better outcome in patients with diabetes undergoing cardiac stress testing</article-title><source>Intern Med J</source><year>2008</year><volume>38</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">17725610</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Wolski</surname><given-names>K</given-names></name><name><surname>Nesto</surname><given-names>R</given-names></name><name><surname>Kupfer</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Jure</surname><given-names>H</given-names></name><name><surname>De Larochelli&#x000e8;re</surname><given-names>R</given-names></name><name><surname>Staniloae</surname><given-names>CS</given-names></name><name><surname>Mavromatis</surname><given-names>K</given-names></name><name><surname>Saw</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Lincoff</surname><given-names>AM</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><article-title>Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial</article-title><source>JAMA</source><year>2008</year><volume>299</volume><fpage>1561</fpage><lpage>1573</lpage><pub-id pub-id-type="pmid">18378631</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Clementi</surname><given-names>F</given-names></name><name><surname>Di Luozzo</surname><given-names>M</given-names></name><name><surname>Mango</surname><given-names>R</given-names></name><name><surname>Luciani</surname><given-names>G</given-names></name><name><surname>Trivisonno</surname><given-names>A</given-names></name><name><surname>Pizzuto</surname><given-names>F</given-names></name><name><surname>Martuscelli</surname><given-names>F</given-names></name><name><surname>Mehta</surname><given-names>JL</given-names></name><name><surname>Romeo</surname><given-names>F</given-names></name><article-title>Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis</article-title><source>J Cardiovasc Med</source><year>2008</year><volume>10</volume><fpage>231</fpage><lpage>237</lpage></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Kao</surname><given-names>J</given-names></name><name><surname>Tobis</surname><given-names>J</given-names></name><name><surname>McClelland</surname><given-names>RL</given-names></name><name><surname>Heaton</surname><given-names>MR</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Currier</surname><given-names>JW</given-names></name><article-title>Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention</article-title><source>Am J Cardiol</source><year>2004</year><volume>93</volume><fpage>1347</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">15165912</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Casscells</surname><given-names>SW</given-names></name><name><surname>Granger</surname><given-names>E</given-names></name><name><surname>Swedorske</surname><given-names>J</given-names></name><name><surname>Goldhammer</surname><given-names>R</given-names></name><name><surname>Shaheen</surname><given-names>M</given-names></name><name><surname>Dorris</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>A</given-names></name><name><surname>Wiktor</surname><given-names>M</given-names></name><article-title>A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003&#x02013;2006</article-title><source>Am J Ther</source><year>2008</year><volume>15</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">18496256</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Melbin</surname><given-names>LG</given-names></name><name><surname>Malmberg</surname><given-names>K</given-names></name><name><surname>Norhammar</surname><given-names>A</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Ryd&#x000e9;n</surname><given-names>L</given-names></name><article-title>The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><fpage>166</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">18156614</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Fisman</surname><given-names>EZ</given-names></name><name><surname>Motro</surname><given-names>M</given-names></name><name><surname>Tenenbaum</surname><given-names>A</given-names></name><article-title>Non-insulin antidiabetic therapy: current problems and future prospects</article-title><source>Adv Cardiol</source><year>2008</year><volume>45</volume><fpage>154</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">18230961</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Garratt</surname><given-names>KN</given-names></name><name><surname>Brady</surname><given-names>PA</given-names></name><name><surname>Hassinger</surname><given-names>NL</given-names></name><name><surname>Grill</surname><given-names>DE</given-names></name><name><surname>Terzic</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names><suffix>Jr</suffix></name><article-title>Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>1999</year><volume>33</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">9935017</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Fosset</surname><given-names>M</given-names></name><name><surname>De Weille</surname><given-names>JR</given-names></name><name><surname>Green</surname><given-names>RD</given-names></name><name><surname>Schmid-Antomarchi</surname><given-names>H</given-names></name><name><surname>Lazdunski</surname><given-names>M</given-names></name><article-title>Antidiabetic sulphonylureas control action potential properties in heart cells via high affinity receptors that are linked to ATP-dependent K+ channels</article-title><source>J Biol Chem</source><year>1988</year><volume>263</volume><fpage>7933</fpage><lpage>7936</lpage><pub-id pub-id-type="pmid">2453509</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Tomai</surname><given-names>F</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Gaspardone</surname><given-names>A</given-names></name><name><surname>Versaci</surname><given-names>F</given-names></name><name><surname>De Paulis</surname><given-names>R</given-names></name><name><surname>Renta a Peppo</surname><given-names>A</given-names></name><name><surname>Chiariello</surname><given-names>L</given-names></name><name><surname>Gioffr&#x000e8;</surname><given-names>PA</given-names></name><article-title>Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker</article-title><source>Circulation</source><year>1994</year><volume>90</volume><fpage>700</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">8044938</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Dreyer</surname><given-names>T</given-names></name><name><surname>Heidt</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>JC</given-names></name><name><surname>Philipp</surname><given-names>M</given-names></name><name><surname>Hehrlein</surname><given-names>FW</given-names></name><name><surname>Katz</surname><given-names>N</given-names></name><name><surname>Al-Fakhri</surname><given-names>N</given-names></name><article-title>Insulin and local growth factor PDGF induce intimal hyperplasia in bypass graft culture models of saphenous vein and internal mammary artery</article-title><source>Eur J Cardiothorac Surg</source><year>2002</year><volume>21</volume><fpage>1002</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">12048077</pub-id></mixed-citation></ref></ref-list></back></article>